Results 111 to 120 of about 170,256 (261)

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

BMC Cancer
Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective inhibitor ...
Primo N. Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri, Robert J. Motzer   +19 more
doaj   +1 more source

Complete Pathologic Response to Neoadjuvant Pembrolizumab Captured on Intraoperative PET/CT: A Case Report and Exploratory Analysis

Head &Neck, EarlyView.
ABSTRACT Background Neoadjuvant immunotherapy is an emerging treatment for patients with head and neck cancer. Given the heterogeneity of response, novel methods of intraoperative tumor and margin assessment warrant investigation. Methods A 55‐year‐old male presented with a cT3N2c supraglottic squamous cell carcinoma with a combined positive score of 5.
Joaquin Austerlitz, Andreja Radevic, Ashtyn McAdoo, Kyrionna Golliday, Cassie Pan, Annie Moroco, Spencer Roark, Michael C. Topf   +7 more
wiley   +1 more source

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

BMC Cancer
Background Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective inhibitor of IDO1.
Irfan Cicin, Elizabeth R. Plimack, Howard Gurney, Raya Leibowitz, Boris Y. Alekseev, Francis X. Parnis, Avivit Peer, Andrea Necchi, Joaquim Bellmunt, Hiroyuki Nishiyama, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Thomas Powles, Cora N. Sternberg   +15 more
doaj   +1 more source

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

BACKGROUND Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet need to improve outcomes in patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or ...
Gary, Dianna, Kim, Sung-Bae, Rapoport, Bernardo, Yam, Clinton, Afshari, Maryam, Bañuelas, Manuel Alejandro Lara, Salvador Bofill, Javier, Schmid, Peter, Tolaney, Sara M, Loi, Sherene, Pistilli, Barbara, Watanabe, Junichiro, Freitas-Junior, Ruffo, Mchayleh, Wassim, Wang, Lu, Lai, Catherine, Kalinsky, Kevin, Guarneri, Valentina, Cescon, David W, Im, Seock-Ah, de Azambuja, Evandro   +20 more
core   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

International Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır, Didem Divriklioğlu, Deniz Can Güven, Gamze Serin Özel, Oğuzhan Yıldız, Gamze Emin, Merve Keskinkılıç, Yeşim Ağyol, Onur Yazdan Balçık, Nagihan Kolkıran, Hale Gülçin Yıldırım Doğan, Pervin Can Şancı, Özge Yalıcı, Teoman Şakalar, Yurdagül Danacı, Yakup Düzköprü, Canan Yıldız, Mesut Yılmaz, İlhan Hacıbekiroğlu, Bülent Erdoğan, Saadettin Kılıçkap, Gamze Gököz Doğu, Melek Karakurt Eryılmaz, Atila Yıldırım, İlhan Öztop, İbrahim Vedat Bayoğlu, Şahnura Uzuntaş, Atike Pınar Erdoğan, Emir Çelik, Devrim Çabuk, Erdoğan Selçuk Şeber, Zehra Sadak Öcal, Hacer Demir   +32 more
wiley   +1 more source

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source

Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy [PDF]

\ua9 2024 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, The Author(s). Introduction: Poly (adenosine diphosphate-ribose) polymerase inhibitors can up-regulate programmed cell death-ligand 1 expression and promote ...
Cobo Dols M, Smagina M, Fedenko A, Zhao B, Gray JE, De Angelis F, Huang Q, Kato T, Hochmair M, Lara-Guerra H, Ozyilkan O, Greystoke A, Schenker M, Nadal E, Leonova V, Rittmeyer A, Aggarwal H, Kim TM   +17 more
core   +3 more sources

A case of severe visual loss related to treatment with pembrolizumab for metastatic renal pelvic cancer

IJU Case Reports
Introduction Pembrolizumab is the standard therapy for urothelial carcinoma treatment; however, adverse events have been noted. Here, we report a rare case of vision loss as an immune‐related adverse event of pembrolizumab therapy in a patient with ...
Naoki Inoue, Mihoko Iitzuka, Hiroki Tanaka, Yudai Ishikawa, Naoko Kawamura, Tetsuo Okuno   +5 more
doaj   +1 more source

Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients

Pharmacological Research
Background: Pembrolizumab is a standard first-line treatment for metastatic non–small cell lung cancer (NSCLC). Although approved dosing regimens achieve near-maximal PD-1 receptor occupancy in clinical trials, variability in pembrolizumab exposure in ...
Cristina Martínez-Toledo, María Jiménez-Meseguer, Marta Molina-Alejandre, Virginia Calvo, Ana Collazo-Lorduy, Belén Sierra-Rodero, Mariola Blanco, Marta Martínez Cutillas, Ángeles Gil-González, Juan Manuel Gutiérrez-Escobedo, Sergio Vázquez Estévez, Natalia Fernández Núñez, Pilar Diz-Taín, María Luisa Garrido Onecha, Natividad Martínez-Banaclocha, Elena Peña, Ana López Martín, Silvia Peña-Cabia, Silvia Sequero-López, Jacobo Rogado, Alfredo Sánchez-Hernández, Juan Coves Sarto, Ángeles Sala González, Xabier Mielgo, Rosa D. García Marrero, Aránzazu García-Grande, Alberto Cruz-Bermúdez, Mariano Provencio   +27 more
doaj   +1 more source